While genetic screening has led to improved clinical outcomes for certain patients, specifically those with APL and CBF AML, the majority of genetic aberrations in AML patients are not targetable with currently available drugs [5, 7, 9–12, 41–43]. Here, CEBPZ is linked to acute myeloid leukemia.